Alexion Pharmaceuticals Beats Estimates With 51 Cent Adjusted EPS (ALXN)

Cheshire, Connecticut-based Alexion Pharmaceuticals, Inc. ALXN released financial results on Thursday morning that beat Wall Street estimates. Alexion Pharmaceuticals, Inc announced that its 4th quarter net income fell to $26.5 million, or 28 cents per share, down from $237.1 million, or $2.59 per share, a year earlier. Excluding special items, the company reported earnings of 51 cents per share. Alexion Pharmaceuticals, Inc reported revenue of $155.98 million, up from $110.65 million a year earlier. According to a poll of analysts by Thomson Reuters, the average Wall Street estimate called for earnings of 50 cents per share, on revenue of $153.68 million. Alexion Pharmaceuticals, Inc. (ALXN) finished the previous trading day at $86.12 per share. The consensus price target of analysts covering the company's stock is $84.78 per share. Alexion Pharmaceuticals, Inc is engaged in the discovery, development and commercialization of therapeutic products aimed at treating patients with a wide array of severe disease states, including hematologic and kidney diseases, neurologic disorders, ophthalmic, transplant, other inflammatory disorders, and cancer. Read more from Benzinga's Company news.